Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients

International Journal of Cancer

Volumn 133, Issue 2, 2013, Pages 408-415

  Na, Keun ^a   Jeong, Seul Ki ^a   Lee, Min Jung ^a   Cho, Sang Yun ^a,d   Kim, Sun A ^b   Lee, Min Ji ^b   Song, Si Young ^b   Kim, Hoguen ^b   Kim, Kyung Sik ^b   Lee, Hyun Woong ^c   Paik, Young Ki ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Chung Ang University   (South Korea)

^d Korea National Institute of Health   (South Korea)

Author keywords

alpha fetoprotein; biomarker; hepatocellular carcinoma; liver carboxylesterase 1

Indexed keywords

ALPHA FETOPROTEIN; CARBOXYLESTERASE; CARBOXYLESTERASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER STAGING; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SOUTH KOREA; STOMACH CANCER;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CARBOXYLIC ESTER HYDROLASES; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEOMICS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84877812899     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28020     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Pang RW, Joh JW, Johnson PJ, et al. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 962-71.
3. Williams R,. Global challenges in liver disease. Hepatology 2006; 44: 521-26.
4. Cabibbo G, Maida M, Genco C, et al. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol 2012; 39: 374-83.
5. Gomaa AI, Khan SA, Leen EL, et al. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 1301-14.
6. Szklaruk J, Silverman PM, Charnsangavej C,. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. AJR Am J Roentgenol 2003; 180: 441-54.
7. Bertino G, Ardiri A, Malaguarnera M, et al. Hepatocellular carcinoma serum markers. Semin Oncol 2012; 39: 410-33.
8. Masuzaki R, Karp SJ, Omata M,. New serum markers of hepatocellular carcinoma. Semin Oncol 2012; 39: 434-9.
9. Patel M, Shariff MI, Ladep NG, et al. Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract 2012; 18: 335-42.
10. Stefaniuk P, Cianciara J, Wiercinska-Drapalo A,. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 418-24.
11. Daniele B, Bencivenga A, Megna AS, et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127: S108-12.
12. Gupta S, Bent S, Kohlwes J,. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46-50.
13. Sherman M,. Pathogenesis and screening for hepatocellular carcinoma. Clin Liver Dis 2004; 8: 419-43.
14. Carr BI, Kanke F, Wise M, et al. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007; 52: 776-82.
15. Sterling RK, Jeffers L, Gordon F, et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009; 7: 104-13.
16. Lopez JB,. Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev 2005; 26: 65-79.
17. Grazi GL, Mazziotti A, Legnani C, et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg 1995; 1: 249-55.
18. Oka H, Saito A, Ito K, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001; 16: 1378-83.
19. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.
20. Satoh T, Hosokawa M,. Structure, function and regulation of carboxylesterases. Chem Biol Interact 2006; 162: 195-211.
21. Xie M, Yang D, Liu L, et al. Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. Drug Metab Dispos 2002; 30: 541-7.
22. Humerickhouse R, Lohrbach K, Li L, et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60: 1189-92.
23. Na K, Lee EY, Lee HJ, et al. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics 2009; 9: 3989-99.
24. Youden WJ,. Index for rating diagnostic tests. Cancer 1950; 3: 32-5.
25. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-5.
26. Aljabiri MR, Lodato F, Burroughs AK,. Surveillance and diagnosis for hepatocellular carcinoma. Liver Transpl 2007; 13: S2-12.
27. Song DS, Bae SH,. Changes of hepatocellular carcinoma guidelines during the last ten-year period. Clin Mol Hepatol 2012; 18: 258-67.
28. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 2001; 35: 421-30.
29. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
30. Sherman M, Takayama Y,. Screening and treatment for hepatocellular carcinoma. Gastroenterol Clin North Am 2004; 33: 671-91.
31. Pontisso P, Quarta S, Caberlotto C, et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006; 119: 735-40.
32. Bencharit S, Morton CL, Hyatt JL, et al. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol 2003; 10: 341-9.
33. Blomme B, Van Steenkiste C, Callewaert N, et al. Alteration of protein glycosylation in liver diseases. J Hepatol 2009; 50: 592-603.
34. Park KS, Kim H, Kim NG, et al. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology 2002; 35: 1459-66.
35. Morita R, Yoshii, M, Nakajima K, et al. Clinical evaluation of serum ferritin to iron ratio in malignant diseases. Eur J Nucl Med 1981; 6: 331-6.
36. Potter PM, Wolverton JS, Morton CL, et al. Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res 1998; 58: 3627-32.
37. Scott DF, Chacko TL, Maxwell DM, et al. Expression and partial purification of a recombinant secretory form of human liver carboxylesterase. Protein Expr Purif 1999; 17: 16-25.